An antibiotic stewardship programme and in-hospital mortality in adults with type 2 diabetes: A randomised controlled trial
Published
December 15, 2024
Paper ID
PAP-000249
Status
Published
DOI
10.65712/tmj.test000507
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on an antibiotic stewardship programme. Methods: Eligible participants were adults with type 2 diabetes. Results: in-hospital mortality occurred in 13% of the intervention group versus 37% of controls. Effects were consistent across prespecified subgroups. Conclusion: These findings suggest that an antibiotic stewardship programme is associated with better in-hospital mortality in adults with type 2 diabetes.
Introduction
The cost of in-hospital mortality to health systems is substantial.
The cost of in-hospital mortality to health systems is substantial. Practice around an antibiotic stewardship programme varies widely between centres. Earlier studies of an antibiotic stewardship programme were small or single-centre.
Discussion
These findings suggest that an antibiotic stewardship programme is associated with better in-hospital mortality in adults with type 2 diabetes. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols.
Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.
Conclusions
An antibiotic stewardship programme merits wider use for adults with type 2 diabetes to improve in-hospital mortality.
References
1. Ibrahim D, Andersen O, et al. Frailty screening and in-hospital mortality. BMJ. 2019;162(12):431-1287.
2. Kowalski G, Kim H, et al. An enhanced recovery pathway and acute kidney injury. Lancet. 2017;344(11):104-1240.
3. Yilmaz U, Nakamura R, et al. Frailty screening and ventilator-free days. Diabetes Care. 2008;248(12):212-1059.
4. Silva I, Okafor Q, et al. Point-of-care ultrasound and patient satisfaction. Ann Intern Med. 2010;321(6):231-1106.
5. Okafor J, Kaur D, et al. Tranexamic acid and time to diagnosis. JAMA. 2021;63(10):741-1585.
Appendices
Supplementary tables are available on request.
Materials and Methods
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
The primary outcome was in-hospital mortality, assessed blind to allocation. We conducted a randomised controlled trial across 7 centres between 2018 and 2021. Missing data were handled with multiple imputation.
We conducted a randomised controlled trial across 10 centres between 2019 and 2025. Missing data were handled with multiple imputation. Eligible participants were adults with type 2 diabetes. The primary outcome was in-hospital mortality, assessed blind to allocation.
Results
3574 participants were included (median age 34 years). The adjusted odds ratio was 0.76 (95% CI 0.46 to 0.84).
| Group | n | Events | Rate % |
|---|---|---|---|
| Age ≥ 65 | 405 | 47 | 37.6 |
| Intervention | 330 | 99 | 20.9 |
| Control | 151 | 10 | 13.3 |
| Centre B | 623 | 20 | 40.9 |
| Female | 311 | 17 | 21.1 |
| Male | 621 | 85 | 20.7 |
| Age ≥ 65 | 304 | 56 | 1.8 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.84 (95% CI 0.50 to 0.60). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.